Joseph Monahan - 01 Feb 2022 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Scientific Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 01 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 03 Feb 2022, 15:49:39 UTC
Previous filing: 02 Sep 2021
Next filing: 11 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+1,050	+1.2%		87,684	01 Feb 2022	Direct	F1
holding	ACRS	Common Stock						193	01 Feb 2022	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-1,050	-100%	$0.000000^*	0	01 Feb 2022	Common Stock	1,050		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The shares underlying these restricted stock units vested on February 1, 2022.